Table 1.

Projected HAV cases by presence of symptoms and resource use, and projected costs, for each vaccination strategy

Projected HAV cases/costs	No vaccination	Single dose	Two doses
Total HAV infections	46,841,960	20,188,993	15,494,178
Anicteric infections	31,664,073	10,456,707	8,723,659
Asymptomatic	15,832,057	5,228,353	4,361,830
Symptomatic	15,832,057	5,228,353	4,361,830
Without medical resource use	7,916,018	2,614,177	2,180,915
With medical resource use	7,916,018	2,614,177	2,180,915
Icteric infections	15,177,887	9,732,286	6,770,519
Not reported	14,154,963	9,076,373	6,314,215
Without medical resource use	758,894	486,614	338,526
With medical resource use	13,396,069	8,589,758	5,975,689
Reported	1,022,924	655,914	456,304
Outpatient care only	963,667	612,780	425,919
Hospitalisation	53,153	38,780	26,966
Fulminant hepatitis	6,103	4,354	3,419
Alive after liver transplant	275	201	158
Alive without liver transplant	2,119	1,506	1,181
Death	3,710	2,647	2,080
Costs, base case (MXN)
Medical treatment costs	12,556,191,424	7,855,880,009	6,275,142,125
Vaccination costs	Not applicable	5,098,632,701	9,432,470,554
Total	12,556,191,424	12,954,512,710	15,707,612,679
Costs, societal perspective (MXN)
Medical treatment costs	12,556,191,424	7,855,880,009	6,275,142,125
Indirect costs	4,178,903,736	2,185,832,885	1,817,758,851
Vaccination costs	Not applicable	5,098,632,701	9,432,470,554
Total	16,735,095,160	15,140,345,595	17,525,371,530

HAV, hepatitis A virus; MXN, Mexican peso. Data on costs are discounted.